Blair William & Co. IL Sells 4,160 Shares of Globus Medical, Inc. (NYSE:GMED)

Blair William & Co. IL lowered its position in Globus Medical, Inc. (NYSE:GMED - Free Report) by 36.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,164 shares of the medical device company's stock after selling 4,160 shares during the period. Blair William & Co. IL's holdings in Globus Medical were worth $593,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. American Century Companies Inc. grew its position in shares of Globus Medical by 255.9% during the 4th quarter. American Century Companies Inc. now owns 103,833 shares of the medical device company's stock valued at $8,588,000 after acquiring an additional 74,659 shares during the period. Oak Thistle LLC bought a new position in Globus Medical during the fourth quarter valued at $376,000. bLong Financial LLC purchased a new stake in Globus Medical in the fourth quarter worth $397,000. Kathmere Capital Management LLC bought a new stake in shares of Globus Medical in the fourth quarter valued at $23,091,000. Finally, State Street Corp raised its stake in shares of Globus Medical by 2.3% in the third quarter. State Street Corp now owns 3,570,726 shares of the medical device company's stock valued at $255,450,000 after buying an additional 81,371 shares during the period. 95.16% of the stock is owned by institutional investors.

Analyst Ratings Changes

GMED has been the topic of a number of recent analyst reports. Truist Financial lowered their price target on shares of Globus Medical from $90.00 to $82.00 and set a "hold" rating on the stock in a report on Tuesday, March 18th. Barclays upped their target price on Globus Medical from $100.00 to $103.00 and gave the stock an "overweight" rating in a research note on Monday, February 24th. Bank of America upgraded Globus Medical from an "underperform" rating to a "neutral" rating and lifted their price target for the company from $80.00 to $97.00 in a research report on Thursday, January 9th. Wells Fargo & Company decreased their price objective on shares of Globus Medical from $95.00 to $93.00 and set an "overweight" rating on the stock in a research report on Friday, February 21st. Finally, StockNews.com lowered shares of Globus Medical from a "buy" rating to a "hold" rating in a research report on Friday, March 21st. Four equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, Globus Medical presently has a consensus rating of "Moderate Buy" and a consensus price target of $97.09.

Insider Activity at Globus Medical

In other news, CFO Keith W. Pfeil sold 14,167 shares of the business's stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $88.29, for a total transaction of $1,250,804.43. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 18.54% of the stock is owned by company insiders.

Globus Medical Stock Down 3.2 %

Shares of NYSE GMED traded down $2.27 during midday trading on Tuesday, reaching $68.48. The company had a trading volume of 1,287,304 shares, compared to its average volume of 1,033,136. The stock has a market cap of $9.42 billion, a PE ratio of 91.31, a price-to-earnings-growth ratio of 1.61 and a beta of 1.28. Globus Medical, Inc. has a one year low of $49.33 and a one year high of $94.93. The firm's fifty day moving average price is $78.77 and its 200-day moving average price is $80.01.

Globus Medical (NYSE:GMED - Get Free Report) last announced its quarterly earnings data on Thursday, February 20th. The medical device company reported $0.84 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.10. The firm had revenue of $657.29 million during the quarter, compared to the consensus estimate of $646.19 million. Globus Medical had a return on equity of 10.83% and a net margin of 4.09%. As a group, equities research analysts expect that Globus Medical, Inc. will post 3.44 EPS for the current year.

Globus Medical Company Profile

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.